Reproducibility and Comparison of DCE-MRI and DCE-CT Perfusion Parameters in a Rat Tumor Model

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and computed tomography (DCE-CT) provide independent measures of biomarkers related to tumor perfusion. We compared the reproducibilities and absolute values of DCE-MRI and DCE-CT biomarkers in the same tumors in an animal model, to investigate the physiologic validity of both approaches. DCE-MRI and DCE-CT were each performed sequentially on three consecutive days in each of twelve rats bearing C6 glioma xenografts. DCE-MRI yielded endothelial transfer constant (Ktrans), extracellular, extravascular space volume fraction (ve), and contrast agent reflux rate constant (kep); and DCE-CT, blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability-surface area product (PS) using Tofts and deconvolution physiological models, with 6.6 and 0.4 seconds temporal resolutions, respectively. Variability in DCE-CT and DCE-MRI were evaluated by variance components analysis. Intra-rat coefficients of variation for DCE-CT parameters BF, BV, MTT and PS were 25%, 22%, 18% and 23%; and for DCE-MRI parameters Ktrans, kep and ve were 23%, 16% and 20%, respectively. Mean (±SD) BF, BV, MTT and PS were: 44.6 (±13.7) ml min−1 100 g−1, 5.7 (±1.5) ml 100 g−1, 10.8 (±2.3) seconds, and 14.6 (±4.7) ml min−1 100 g−1, respectively. Mean (±SD) Ktrans, kep and ve were: 0.21 (±0.05) min−1, 0.68 (±0.14) min−1, and 0.29 (±0.06), respectively. Permeability estimates from DCE-MRI (Ktrans) were 44% higher than from DCE-CT (PS), despite application of appropriate corrections. DCE-MRI and DCE-CT biomarkers of tumor perfusion have similar reproducibilities suggesting that they may have comparable utility, but their derived parameter values are not equivalent.

[1]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[2]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Geoff J M Parker,et al.  Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.

[4]  Rajesh Odedra,et al.  Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. , 2009, Magnetic resonance imaging.

[5]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[7]  Alan Jackson,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology , 2005 .

[8]  Edward Ashton,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2012, Definitions.

[9]  R. Craen,et al.  Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. , 1999, Journal of computer assisted tomography.

[10]  Joanna Leadbetter,et al.  Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 , 2004, Clinical Cancer Research.

[11]  J. Waterton,et al.  Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast‐enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol) , 2008, NMR in biomedicine.

[12]  C. Ng,et al.  Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. , 2010, AJR. American journal of roentgenology.

[13]  C. Dick,et al.  X-ray attenuation properties of radiographic contrast media. , 1987, Medical physics.

[14]  Ting-Yim Lee Functional CT: physiological models , 2002 .

[15]  J R Griffiths,et al.  Clinical studies. , 2005, Advances in pharmacology.

[16]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  T. Purdie,et al.  Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. , 2001, Physics in medicine and biology.

[18]  R. Herbst,et al.  Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography: A Comparison Study , 2009, Journal of computer assisted tomography.

[19]  J R Griffiths,et al.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.

[20]  Edward F. Jackson,et al.  A phase I surrogate endpoint study of SU6668 in patients with solid tumors , 2004, Investigational New Drugs.

[21]  R. Craen,et al.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. , 2000, AJNR. American journal of neuroradiology.

[22]  J. Waterton,et al.  Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours , 2003, British Journal of Cancer.

[23]  P. Tofts,et al.  Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA MRI. , 1992, Investigative ophthalmology & visual science.

[24]  R. Craen,et al.  Dynamic CT measurement of cerebral blood flow: a validation study. , 1999, AJNR. American journal of neuroradiology.